Formycon AG

Formycon Reports Further Course of Capital Measure

Public disclosure of inside information according to article 17 MAR

Munich (pta039/26.06.2019/18:15) - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) is today reporting on the further course of the capital measure approved on March 22, 2019 by the Executive Board and Supervisory Board and entered into the commercial register on April 10, 2019, under the terms of which the company's share capital has been increased by EUR 577,397.00 from EUR 9,422,603.00 to EUR 10,000,000.00 with partial utilization of the approved capital through the issue of 577,397 new, bearer shares with a calculated proportion of the share capital of EUR 1.00 apiece and an issue amount of EUR 29.90 per share in return for cash investment.

On June 3, 2019, Formycon announced that its investor M&H Equity AG, based in Heerbrugg, Switzerland, had so far paid in EUR 577,397.00 as nominal payments and EUR 4,422,603.00 as a debt contribution, totaling EUR 5,000,000.00, to the company's capital increase account and a further debt contribution amounting to EUR 12,264,170.30 was still outstanding. With the agreement dated June 26, 2019, Wendeln & Cie. KG, an asset management company of Mr. Peter Wendeln (anchor shareholder and long-standing member of the Supervisory Board of Formycon AG), acquired all rights from the certificate of subscription as well as the 577,397 shares in Formycon AG from the cash capital increase.

Even before this transaction, Mr. Peter Wendeln and the companies to be assigned to him were the largest investor group of Formycon AG. The acquisition of the 577,397 shares increases their shareholding from around 18.9 percent to around 24.6 percent.

Formycon AG very much welcomes the implementation of the transaction and regards the expansion of the involvement of a long-standing strategic partner as a strong signal and a great sign of confidence in the company.

About Formycon:
Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development.